Greenyn Biotechnology Co., Ltd
Greenyn Biotechnology Co., Ltd, a dietary supplement company, develops, manufactures, and sells health products in Taiwan and internationally. The company offers proprietary ingredients, such as Insumate, a bitter melon extract; Antromax, an antrodia cinnamomea; and Zymologist 101 Phyto fermented drink. It also provides functional formulas for youth and beauty series, digestive health series, bra… Read more
Greenyn Biotechnology Co., Ltd (6846) - Net Assets
Latest net assets as of : NT$- TWD
Based on the latest financial reports, Greenyn Biotechnology Co., Ltd (6846) has net assets worth NT$- TWD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$-) and total liabilities (NT$-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Greenyn Biotechnology Co., Ltd - Net Assets Trend (None–None)
This chart illustrates how Greenyn Biotechnology Co., Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Greenyn Biotechnology Co., Ltd (None–None)
The table below shows the annual net assets of Greenyn Biotechnology Co., Ltd from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Greenyn Biotechnology Co., Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Greenyn Biotechnology Co., Ltd Competitors by Market Cap
The table below lists competitors of Greenyn Biotechnology Co., Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cuu Long Pharmaceutical JSC
VN:DCL
|
$20.97K |
|
Goldenstone Acquisition Limited Warrants
NASDAQ:GDSTW
|
$20.98K |
|
Med Life S.A.
F:O0C
|
$20.98K |
|
E-Elements Technology Co., Ltd.
TWO:6842
|
$21.01K |
|
Matba Rofex SA
BA:MTR
|
$20.96K |
|
Regal Investment Fund
AU:RF1
|
$20.94K |
|
SRNA3F
SA:SRNA3F
|
$20.94K |
|
Kwang Hee Self-Administered Real Estate
KO:140910
|
$20.93K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Greenyn Biotechnology Co., Ltd's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Greenyn Biotechnology Co., Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Greenyn Biotechnology Co., Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Greenyn Biotechnology Co., Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Greenyn Biotechnology Co., Ltd (6846) | NT$- | N/A | N/A | $20.97K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |